BRIEF published on 04/23/2025 at 20:35, 3 days 2 hours ago GenSight Biologics Announces Annual General Meeting Details Annual General Meeting Shareholders Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 04/23/2025 at 20:30, 3 days 2 hours ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 13, 2025 at 2:00 pm CEST in Paris, France. Procedures for obtaining preparatory documents outlined Annual General Meeting Preparatory Documents GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 04/08/2025 at 07:51, 18 days 15 hours ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
BRIEF published on 04/08/2025 at 07:48, 18 days 15 hours ago GenSight Biologics Files 2024 Universal Registration Document Universal Registration Document GenSight Biologics Gene Therapies Retinal Diseases Financial Report 2024
PRESS RELEASE published on 04/08/2025 at 07:43, 18 days 15 hours ago INSIDE INFORMATION / OTHER NEWS RELEASES GenSight Biologics announces the filing of its 2024 Universal Registration Document with the French market authority, including financial reports and corporate governance details GenSight Biologics Gene Therapies Retinal Neurodegenerative Diseases 2024 Universal Registration Document Central Nervous System Disorders
BRIEF published on 04/07/2025 at 20:19, 19 days 3 hours ago GenSight Biologics Financial and Business Update Fundraising Clinical Trials Gene Therapy Financial Update GenSight Biologics
PRESS RELEASE published on 04/07/2025 at 20:14, 19 days 3 hours ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and business update as of March 31, 2025. Discussions with French agency progressing. Fundraising planned for Phase III trial and marketing advancement Business Update Cash Position Fundraising Activities GenSight Biologics RECOVER Phase III Trial
BRIEF published on 03/17/2025 at 07:35, 1 month 9 days ago GenSight Biologics Presents LUMEVOQ® at NANOS 2025 Gene Therapy GenSight Biologics LUMEVOQ® NOHL NANOS Congress
PRESS RELEASE published on 03/17/2025 at 07:30, 1 month 9 days ago Inside Information / Other news releases GenSight Biologics will present scientific updates on LUMEVOQ gene therapy at NANOS 2025, including real-world experience and long-term outcomes for LHON treatment Gene Therapy GenSight Biologics LHON LUMEVOQ NANOS 2025
BRIEF published on 03/07/2025 at 08:34, 1 month 19 days ago GenSight Biologics Secures €0.9 Million Financing from Existing Investors Investors Financing Gene Therapy GenSight Biologics Retinal Diseases
Published on 04/26/2025 at 02:00, 21 hours 29 minutes ago Battery X Metals Announces Strategic Agreement to Advance Artificial Intelligence-Driven Exploration of Critical Battery Metals in Nevada, USA
Published on 04/25/2025 at 23:30, 23 hours 59 minutes ago AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Published on 04/25/2025 at 23:01, 1 day ago Medicure Reports Financial Results for Quarter and Year Ended December 31, 2024
Published on 04/25/2025 at 23:00, 1 day ago AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Published on 04/25/2025 at 22:15, 1 day 1 hour ago Grande Portage Resources Announces Extension of Expiry Date for Warrants
Published on 04/25/2025 at 22:47, 1 day ago DEAG achieves new revenue level in “transformation year” 2024 – Strategic investments and strong start to the year create basis for future sustainable growth
Published on 04/25/2025 at 20:30, 1 day 2 hours ago EQS-Adhoc: Nagarro SE: Confirms 2024 guidance and dividend, postpones publication for full-year results
Published on 04/25/2025 at 18:44, 1 day 4 hours ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 04/25/2025 at 18:31, 1 day 4 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/25/2025 at 18:30, 1 day 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/25/2025 at 18:05, 1 day 5 hours ago Louis Hachette Group - 2025 First-quarter revenue
Published on 04/25/2025 at 18:00, 1 day 5 hours ago Availability of the 2024 universal registration document
Published on 04/25/2025 at 18:00, 1 day 5 hours ago Postponement of the publication of the annual financial statements
Published on 04/25/2025 at 17:45, 1 day 5 hours ago LANSON-BCC: GENERAL SHAREHOLDERS’ MEETING ON APRIL 25, 2025 - DIVIDEND: €0.90 PER SHARE
